
Braveheart Bio, Inc.
BRVENASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
21.51 US$
+0.32 US$ · +1.51%
BRVE نظرة عامة على الشركة
ملف الشركة
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.



















